First Inventor

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
Patent and Trademark Office: U S DEPARTMENT OF COMMERCE

red to respond to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are req 6040/80679 Attorney Docket No. BRUCE A. FOGELSON

PATENT APPLICATION **TRANSMITTAL**

م ہ Title BUILDERS ON-LINE ASSISTANT EL709888724US Express Mail Label No. visional applications under 37 CFR 1.53(b))

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.	ADDRESS TO: Assistant Commissioner for Patents 10 Box Patent Application Washington, D.C. 20231					
Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original, and a duplicate for fee processing)	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)					
Applicant claims small entity status. See 37 CFR 1.27.	 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) 					
3. Specification [Total Peges 40] Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Feed sponsored R & D - Reference to sequence listing, a table - Reference -	a. Computer Readable Form (CRF) b. Specification Sequence Listing on: i. CD-ROM or CD-R (2 copies), or ii. paper c. Statements verifying identity of above copies ACCOMPANYING APPLICATION PARTS 9. Assignment Papers (cover sheet & document(s)) 10. (when there is an assignee) 11. English Translation Document (of applicable) 12. Statement ((IS)SPTO-1449 Copies of IDS statement (IS)STO-1449 Copies of IDS (Statement (IS)STO-1449 (IS)STO-144					
Signed statement attached deleting inventor named in the prior application, see 37 CFR 1.83(d)(2) and 1.33(b). Application Data Sheet. See 37 CFR 1.76	or its equivalent. 17. Other: Appendices I, II AND III					
18. If a CONTINUING APPLICATION, check appropriate box, and or in an Application Data Sheet under 37 CFR 178 Continuation Divisional Continuation-in-propriate policy and in a propriate programme of the propriate propriate programme of the propriate propriate programme of the propriate programme of the propriate propriate programme of the propriate programme. The disclosure of the accompanies of the propriate programme on the propriate programme. The incorporation can only be relief upon when a portion to	aupply the requisite information below and in a preliminary amendment, art (CIP) of prior application No.: / Group / Art Unit ure of the prior application, from which an oath or declaration is supplied anying continuation or divisional application and is hereby incorporated by as been inadvertably omitted from its submitted application parts.					
19. CORRESPO	ONDENCE ADDRESS					
Customer Number or Bar Code Label	or X Correspondence address below					
Jon P. Christensen 2462	8					
Name PATENT_TRADEMAR	IK OFFICE					
Address WELSH & KATZ, LTD.						
120 South Riverside Plaza - 22nd Floor	Illinois Zin Code 60606					
City Chicago State	IIIII OID					
Country U.S.A. Telephone	(312) 655-1500 Fax (312) 655-1501					
Name (Pnnt/Type) Jon P. Christensen Registration No. (Altomey/Agent) 34,137						
Cimpature (1)	Date January 24, 2001					

Burden Hour Statement: Thief form is estimated to take 0.2 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the amount of size you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SBIT (11.00)
Approved for use through 103 12000, OMB 0981-0030
Approved for use through 103 12000
Approved **TRANSMITTAI** Complete if Known for FY 2001 Application Number Filing Date January 24, 2001 First Named Inventor BRUCE A. FOGELSON Patent fees are subject to annual revision. Examiner Name Group Art Unit \$998.00 TOTAL AMOUNT OF PAYMENT Attornov Docket No. 6040/80679

7.1(0110) 9.00102, 130.								
METHOD OF PAYMENT		FEE CALCULATION (continued)						
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:		3. ADDITIONAL FEES Large Entity Small Entity						
Deposit Account 23-0920	Fee	Feé	Fee	Fee	Fee Description	Fee Paid		
Number 23-0920	Code 105	(\$) 130	Code 205	(\$) 65	Surcharge - late filing fee or oath			
Deposit Account WELSH & KATZ, LTD.	127	50	227	25	Surcharge - late provisional filing fee or cover sheet			
Name Charge Any Additional Fee Required	139	130	139	130	Non - English specification			
Under 37 CFR §§ 1 16 and 1 17	147	2,520	147	2,520	For filing a request for ex parte reexamination			
Applicant claims small entity status See 37 CFR § 1 27	112	920*	112	920*	Requesting publication of SIR prior to Examiner action			
2. Payment Enclosed:	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action			
Check Credit card Money Other	115	110	215	55	Extension for reply within first month			
FEE CALCULATION	116	390	216	195	Extension for reply within second month			
1. BASIC FILING FEE	117	890	217	445	Extension for reply within third month			
Large Entity Small Entity	118	1,390	218	695	Extension for reply within fourth month			
Fee Fee Fee Fee Description	128	1,890	228	945	Extension for reply within fifth month			
Code (\$) Code (\$) Fee Pald 101 710 201 355 Utility filing fee 355.00	119	310	219	155	Notice of Appeal			
106 320 206 160 Design filing fee	120	310	220	155	Filing a brief in support of an appeal			
107 490 207 245 Plant filing fee	121	270	221	135	Request for oral hearing			
108 710 208 355 Reissue films fee	138	1,510	138	1,510	Petition to institute a public use proceeding			
114 150 214 75 Provisional filing fee	140	110	240	55	Petition to revive - unavoidable			
SUBTOTAL (1) \$355.00	141	1,240	241	620	Petition to revive - unintentional			
	142	1,240	242	620	Utility issue fee (or reissue)			
2. EXTRA CLAIM FEES Fee from	143	440	243	220	Design issue fee			
Extra Claims below Fee Pald	144	600	244	300	Plant issue fee			
Total Claims 36 -20** = 16 X 9.00 = 144.00	122	130	122	130	Petitions to the Commissioner			
Independent 3 - 3** = 0 X = 0.00	123	50	123	50	Processing fee under 37 CFR § 1.17(q)			
Multiple Dependent = Large Entity Small Entity	126	180	126	180	Submission of Information Disclosure Statement			
Fee Fee Fee Fee Description Code (\$) Code (\$)	581	40	581		Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))			
102 80 202 40 Independent claims in excess of 3 104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))			
109 80 209 40 ** Reissue independent claims	179	710	279	355	Request for Continued Examination (RCE)			
over original patent	169	900	169	900	Request for expedited examination of a design application			
110 18 210 9 ** Reissue claims in excess of 20 and over original patent	Oth	er fee	(specif	0				
SUBTOTAL (2) \$144.00	1							
**or number previously paid, if greater, For Reissues, see above	SUBTOTAL (3) S499 00							
or number previously paid, it greater, For Reissdes, see above			-					

SUBMITTED BY (312) 655-1500 34,137 Telephone Name (Print/Type Jon P. Christenser (Attorney/Agent) Date January 24, 2001 Signature

> WARNING: Intermation on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Official, Patient and Trademark Office, Washington, DC 20231 DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assignation Commissioner for Patients, Washington, DC 20231 DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assignation Commissioner for Patients, Washington, DC 20231.